Home » Posts tagged 'NTCD-M3'
Tag Archives: NTCD-M3
Destiny Pharma #DEST – Developing Novel Medicines that Prevent Serious Infections. Alan Green talks to CEO Neil Clark
- Two exciting late stage clinical assets – XF-73 and NTCD-M3
- China Medical Systems – new XF-73 programme in China
- NTCD-M3 Phase 3 studies
- Spore COV – JV progress and Innovate funding
- Cash runway and upcoming value inflection points